Heron Therapeutics, Inc.

    Jurisdiction
    United States
    LEI
    549300DR2I1DOPD2IX53
    ISIN
    US4277461020 (HRTX)
    Sectors
    1. Healthcare
    2. Biotechnology

    Scores

    InsiderPie Expert Score
    52 / 100
    Better than peer group:
    50 / 100
    Fair value (Benjamin Graham formula)
    N/A
    Financial strength (Piotroski F-Value)
    4 / 9
    Fundamental strength relative to industry (Mohanram G-Value)
    3 / 7

    Profile

    Heron Therapeutics, Inc., a biotechnology company, engages in developing treatments to address unmet patient needs. Read full profile

    Fundamentals

    Net revenue
    €127.68M
    Gross margin
    74.6%
    EBIT
    €1.05M
    EBIT margin
    0.8%
    Net income
    -€794.10K
    Net margin
    -0.6%

    Statement period: - (published )

    Estimates

    Fiscal Year Net revenue Net income
    €150.80M +18.1% €9.44M -1,289.0%
    €179.12M +18.8% €33.80M +258.0%
    €213.18M +19.0% €60.45M +78.8%

    Stock price

    Stock price loading... No stock price available Stock price provided by Lang & Schwarz Steigende Zinsen und niedrigere Bewertungen für Wachstumsaktien im Allgemeinen Eine Gewinnwarnung beim Konkurrenten Adyen signalisiert eine Abkühlung des europäischen Markts für Zahlungsdienstleistungen. Eine Gewinnwarnung von Wordline SA triggert einen massiven Kursverlust.

    Configure chart

    Adjust colors to be more accessible for red-green-colorblind users.
    Scale
    Moving average Display a moving average line on the chart.

    Dividends

    No dividend payouts

    Analyst ratings

    No analyst ratings available

    Insider Transactions

    Name Title Transaction Date Shares Price Value
    Morgan Adam N/A +1.8M $1.50 +$2.65M

    Earnings Calls

    Investor transactions

    Name Shares Value Last change Change type
    Peter Brown 2.3M $5.00M +1.1M Buy

    Earnings Calls

    Latest earnings call: May 7, 2024 (Q1 2024)

    Add to watchlist

    Notifications